AU2003235191B2 - Papilloma virus-like particles, fusion proteins as well as processes for their production - Google Patents
Papilloma virus-like particles, fusion proteins as well as processes for their production Download PDFInfo
- Publication number
- AU2003235191B2 AU2003235191B2 AU2003235191A AU2003235191A AU2003235191B2 AU 2003235191 B2 AU2003235191 B2 AU 2003235191B2 AU 2003235191 A AU2003235191 A AU 2003235191A AU 2003235191 A AU2003235191 A AU 2003235191A AU 2003235191 B2 AU2003235191 B2 AU 2003235191B2
- Authority
- AU
- Australia
- Prior art keywords
- virus
- proteins
- protein
- particles
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired, expires
Links
- 239000002245 particle Substances 0.000 title claims description 74
- 238000004519 manufacturing process Methods 0.000 title claims description 31
- 238000000034 method Methods 0.000 title claims description 25
- 208000003154 papilloma Diseases 0.000 title claims description 20
- 108020001507 fusion proteins Proteins 0.000 title description 37
- 102000037865 fusion proteins Human genes 0.000 title description 37
- 108090000623 proteins and genes Proteins 0.000 claims description 161
- 102000004169 proteins and genes Human genes 0.000 claims description 160
- 241001631646 Papillomaviridae Species 0.000 claims description 30
- 238000012217 deletion Methods 0.000 claims description 21
- 230000037430 deletion Effects 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 238000002255 vaccination Methods 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 241000701822 Bovine papillomavirus Species 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 12
- 210000004899 c-terminal region Anatomy 0.000 claims description 11
- 230000000069 prophylactic effect Effects 0.000 claims description 11
- 241000701447 unidentified baculovirus Species 0.000 claims description 10
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 9
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 9
- 108010087302 Viral Structural Proteins Proteins 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 208000007089 vaccinia Diseases 0.000 claims description 9
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 7
- 241000388186 Deltapapillomavirus 4 Species 0.000 claims description 7
- 210000000805 cytoplasm Anatomy 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 229920002113 octoxynol Polymers 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 238000004925 denaturation Methods 0.000 claims description 3
- 230000036425 denaturation Effects 0.000 claims description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 2
- 238000004153 renaturation Methods 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 2
- 108091006629 SLC13A2 Proteins 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 134
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 35
- 239000012634 fragment Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 208000019065 cervical carcinoma Diseases 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 208000015698 cervical squamous intraepithelial neoplasia Diseases 0.000 description 6
- 208000009608 Papillomavirus Infections Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 241000701806 Human papillomavirus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 206010059313 Anogenital warts Diseases 0.000 description 3
- 208000000907 Condylomata Acuminata Diseases 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 206010061978 Genital lesion Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710132637 Protein C2 Proteins 0.000 description 2
- 101710132697 Protein L2 Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 101710195626 Transcriptional activator protein Proteins 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 2
- 201000004201 anogenital venereal wart Diseases 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000701646 Kappapapillomavirus 2 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 229940037642 autologous vaccine Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
I
-1-
AUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT
ORIGINAL
Name of Applicant/s: Actual Inventor/s: Address for Service:
CCN:
Loyola University of Chicago Lutz Gissmann and Jian Zhou and Martin Muller and Jeanette Painstil Baldwin Shelston Waters MARGARET STREET SYDNEY NSW 2000 3710000352 PAPILOMA VIRUS-LIKE PARTICLES, FUSION PROTEINS AS WELL AS PROCESSES FOR THEIR PRODUCTION Invention Title: Details of Original Application No. 10106/00 dated 05 Jan 2000 The following statement is a full description of this invention, including the best method of performing it known to me/us:- File: 27330AUP01 500212739_1 DOC/5844 la- PAPILLOMA VIRUS-LIKE PARTICLES, FUSION PROTEINS AS WELL AS PROCESSES FOR THEIR PRODUCTION Description The present application is a divisional application of Australian Application No.
10106/00 which is incorporated in its entirety herein by reference.
Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.
The invention relates to recombinantly produced papilloma virus-like particles, proteins, fusion proteins as well as processes for the formation and purification of these particles, proteins and fusion proteins.
Infections with certain (high-risk) types of genital papilloma viruses in humans (HPV), eg. HPV 16, 18 or 45 are held to be the main risk factor for the formation of malignant tumours of the anogenital tract. Of these, cervical carcinoma is by far the most frequently occurring. According to an estimate by the WHO, about halfa million new cases of this disease occur annually. Because of this frequent occurrence, the connection between HPV infection and cervical carcinoma has been the best investigated: a) Precursor lesions of cervical carcinoma (cervical intraepithelial neoplasia: CIN) are caused by papilloma virus infections.
b) The genomes of certain HPV types (eg. 16, 18, 33, 35, 45) have been proven to occur in more than 95% of tumour biopsies as well as in cell lines derived from them.
Depending on the geographic origin of the tumours, 50-70% of these contain HPV 16.
c) In all subsequently examined cases the ORFs E6 and E7 are transcribed (Wettstein et al., in Pfister H. Papilloma viruses and human cancer, pp. 155 to 179, Boca Raton, 1990).
d) The proteins E6 and E7 can be proven in all cervical-carcinoma cell-lines as well as in in vitro transformed human keratinocytes, and the majority of patients with cervical carcinoma have E6- or E7-specific antibodies.
e) The constitutive expression of the E6/E7 proteins is necessary to maintain the transformed condition of HPV-positive tumours.
lbf) The E6- and E7 genes of HPV 16 and HPV 18 are biologically active in the following experimental systems: -Induction of cellular DNA synthesis in human cells; -Transformation of human keratinocytes and other cells in culture; Tumour formation in transgenic mice.
Other HPV types (principally HPV 6 and 11) cause benign genital warts (condylomata acuminata) and are only extremely rarely associated with malignant tumours (low-risk types).
As a rule, genital papilloma viruses in humans are transmitted during intercourse and in most cases lead to persistent infection in the anogenital mucous membrane. This led to the conclusion that primary infections induce only an insufficient immune response, or that the virus has developed possibilities of avoiding the immune surveillance in the infected cells. On the other hand there are good indications suggesting that the immune system is involved during primary manifestation or
I
during the malignant progression of papilloma virus infections. (For an overview see Altmann et al.
(1994) in Minson Neil McCrae M. (eds): Viruses and cancer, Cambridge University Press, pp.
71 to a) In the case of animal papilloma viruses (rabbit papilloma virus and bovine papilloma s virus), the clinical manifestation of primary infections can be avoided by vaccination with viral structural proteins or with wart extracts (autologous vaccines).
b) Rodents are protected by vaccination with HPV 16 E6- or E7-positive vaccinia recombinants or by synthetic peptides prior to tumour formation after inoculation of HPV 16transformed autologous cells.
o1 c) Regression of warts is often systemic and in the case of animal papilloma viruses can be induced by the transfer of lymphocytes of regressor animals.
d) In the case of immuno-suppressed patients (eg. kidney transplantees or HIV-infected persons), the incidence of genital warts, CIN and anogenital cancer is increased.
This led to the conclusion that papilloma virus-specific vaccinations aimed at preventing the primary infection and the occurrence of genital cancer should be possible.
1. Avoidance of HPV infections s suitable by vaccination with the structural proteins L1 and L2 of the papilloma virus (prophylactic vaccination).
Because papilloma viruses cannot be propagated to adequate titres in cell cultures or other experimental systems, the viral proteins can only be produced by means of recombinant vectors.
Recently, virus-like particles (VLPs) which, after expression of the viral structure proteins L1 and L2 (or L1 on its own), are formed in recombinant vaccinia or baculovirus, have been described.
Purification of the VLPs can be achieved very simply by means of centrifugation in CsCI or sucrose gradients.
WO 93/02184 describes a method which provides papilloma virus-like particles (VLPs), which are used for diagnostic applications or as a vaccine against infections caused by the papilloma virus.
WO 94/00152 describes a recombinantly produced L1 main capsid protein which mimics the conformational neutralising epitope on human and animal papilloma virions. These recombinant proteins can be used as vaccines which protect against papilloma virus infections.
2. Treatment of cervical carcinoma or precursor lesions by immunotherapy assisted by early papilloma virus-proteins (principally E6 or E7) which are expressed in the persistently infected cells (therapeutic vaccination).
It is assumed that by this vaccination, cytotoxic T-cells are activated against persistently infected genital lesions, The target population are patients with HPV associated pre-malignant or malignant genital lesions.
-3- Early HPV proteins are produced by expression in E. coli or eukaryotic vectors (eg. baculovirus or yeast). Purification is however rendered difficult by the low solubility and as a rule requires a combination of ion exchange chromatography, gel filtration and affinity chromatography.
PCT patent application WO 93/20844 discloses that the E7 protein of the papilloma virus from HPV or BPV is therapeutically effective in the regression (not however in the prevention) of papilloma virus-tumours in mammals. In addition, preferred antigenic protein fragment sequences are described.
So far, however, no VLPs were described which are suitable both for prophylactic and therapeutic vaccination. The last-mentioned processes have the disadvantage that, for example, early HPV proteins, because of their low solubility, can only be cleaned with difficulty.
A high particle production would be particularly desirable, in particular in view of a vaccine for prophylactic and therapeutic vaccination.
A disadvantage of the process described so far was that it was not possible to produce VLPs after expression of L1 in E. coli.
It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.
Summary of the Invention It is therefore advantageous to make available recombinantly produced proteins as well as VLPs which are suitable as a vaccine for prophylactic and therapeutic vaccination, as well as processes for the production of these proteins and VLPs.
Equally, simple purification of the recombinant proteins obtained should be possible.
Also production of VLPs after expression of L1 in E. coli should be possible.
Accordingly, a first aspect of the present invention provides recombinantly produced papilloma virus-like particles which are formed after expression of viral structural proteins LI and/or L2, wherein one or more sections of the Ll and/or L2 proteins are deleted without loss of the ability to form virus-like particles.
According to a second aspect, the invention provides the virus-like particles according to the first aspect of the invention, wherein the deleted section in the L1 protein is one or more of amino acid sequences 311-351, 331-371, 391-431 of the bovine papilloma virus type 1.
-3a- According to a third aspect, the invention provides recombinantly produced papilloma virus-like particles which are formed after expression of viral structural proteins L1 and/or L2, wherein one or more sections of the L1 and/or L2 proteins are deleted and the ability to form virus-like particles is increased in comparison to native formation and/or in vitro production.
According to a fourth aspect, the invention provides the virus-like particles according to the invention, wherein the deleted section in the C-terminal section in the L1 and/or L2 protein relates to an amino acid sequence approximately 1 to 34 amino acids in length of a papilloma virus.
According to a fifth aspect, the invention provides a process for the production of papilloma virus-like particles according to the invention, wherein the expression of L1 and/or L2 proteins is carried out in viral, eukaryotic or prokaryotic vectors, Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".
Description of the Preferred Embodiments There is also disclosed herein recombinantly produced papilloma virus-like particles which are formed after expression of the viral structural proteins L and/or L2, whereby one or several sections of the L1 and/or L2 proteins are deleted and the ability to form virus-like particles remains, characterised in that the deleted section of L1 and/or L2 proteins is replaced by other proteins or protein fragments, in order to obtain a fusion protein.
There is also disclosed recombinantly produced papilloma virus-like particles which are formed after expression of the viral structural proteins L1 and/or L2, whereby one or several sections of the L1 and/or L2 proteins are deleted and the ability to form virus-like particles is increased in comparison to the native formation and/or in vitro production, characterised in that the deleted section of L1 and/or L2 proteins is replaced by other proteins or protein fragments, in order to obtain a fusion protein.
According to the present invention, VLPs are produced which consist of fusion proteins of late and early HPV proteins (or fragments thereof) (HVLP) and which can be 3b used for prophylactic or therapeutic vaccination. Such a vaccine offers the following advantages when compared with conventional preparations: a) In the case of prophylactic vaccination, HVLPs, through induction of L1/L2-specific antibodies not only prevent entry of the virus into the cell but they also eliminate already infected cells (through induction of cytotoxic T-cells) if an infection has taken place earlier or if the humoral immune response was inadequate.
b) In the case of therapeutic vaccination, HVLPs eliminate persistently infected cells (eg. in patients with CIN or cervical carcinoma), and above all hey prevent re-infection in female patients with CIN lesions.
c) Purification of the HVLPs is simple, in a similar way to purification of the VLPs without s early HPV proteins.
According to the present invention, VLPs of the bovine papilloma virus (BPV).type 1 and the human papilloma viruses 11 and 16 after expression of L1 plus L2, or of L1 on its own, can be produced in vaccinia or baculovirus. Experiments show that parts of the L1 protein can be deleted (amino acid sequence 311-351, 331-371, 391-431 of BPV 1; 306-315 of HPV 16), without the ability to to form VLPs being lost. Such sections exist in the L1 proteins of all papilloma viruses so that the deleted section of L1 can be replaced by other proteins (of papilloma viruses or of other origin) and that in this way, hybrid virus-like particles can be produced. In the same way, parts of the papilloma virus protein L2 are deleted and replaced by other (early HPV or other) proteins, so that HVLPs can also be formed from the complete L1 protein plus an L2 fusion protein.
is Fusion proteins comprising deleted L1 or L2 protein from different HPV types (principally HPV 6, 11, 16, 18, 33, 35, 45) and the respective early proteins El, E2, E4, E5, E6, E7 (or parts thereof) are produced by expression in vaccinia recombinants which can be constructed in a very short time.
The formation of VLPs, consisting either of a L1 fusion protein or of the complete L1 protein plus an L2 fusion protein, is monitored by electron microscopy, and the presence of the early HPV protein is tested by Western blot analysis by means of specific antisera. For large-scale production of HPLVs the expression of the proteins is carried out in viral or eukaryotic systems, preferably in baculovirus or in yeast.
Respective experiments for producing fusion proteins can be carried out with proteins of other origin.
Essential for the present invention are recombinantly produced virus-like particles (VLPs) which are formed after expression of the viral structural proteins L1 and/or L2, whereby sections of the L1 and/or L2 protein are deleted, without the ability of forming VLPs being lost.
According to the present invention, the deleted section in the L1 protein of the bovine papilloma virus type 1 preferably concems the amino acid sequences 311-351, 331-371, 391-431. In the case of L1 proteins of the human papilloma virus 16, it advantageously concerns the amino acid sequence 306-315.
In a preferred embodiment of the present invention the deleted section of L1 and/or L2 proteins are replaced by other proteins or protein fragments, whereby fusion proteins are obtained. The share of L1 or L2 proteins is advantageously approx. 50 to 99%, preferably approx. 60 to 90%, particularly preferred approx. However,, according to the present invention, even if this is not explicitly stated below, more than one section of the L1 and/or L2 protein should also be deleted and preferably be replaced by other proteins or protein fragments.
It is particularly preferred to replace the deleted section in the L1 or L2 protein by other proteins Sof papilloma viruses and/or proteins of other origin, whereby hybrid virus-like particles (HVLPs) can be produced.
it has been shown to be particularly favourable according to the present invention, if the formation of the VLPs is from an L1 fusion protein or, according to a further embodiment, from a complete L1 protein and an L2 fusion protein.
The fusion proteins, in particular for the formation of hybrid virus-like particles according to a further embodiment of the present invention, preferably consist of a deleted L1 and/or L2 protein of different HPV types (human papilloma virus), particularly preferred are HPV 6, 11, 16, 18, 33, 35 and and other proteins or protein fragments. Preferably these other proteins or protein fragments concern respective early proteins or fragments thereof, such as for example the early proteins El, E2, E4, E5, E6 and/or E7.
According to the process covered in the invention, the expression of the fusion proteins and proteins is carried out in viral or eukaryotic vectors; particularly preferred in baculoviruses or in yeasts.
According to a further embodiment of the process according to the invention, the fusion proteins are produced through expression in vaccinia recombinants.
According to the present invention, the application of the fusion proteins or the hybrid virus-like particles for the production of a prophylactic and therapeutic vaccine preferably takes place after adding further components.
Up to now, for the production of VLPs, such as for example of VLPs from HPV 16, the L1 (ORF) was expressed by means of eukaryotic vectors, such as for example baculovirus. Formation of.the VLPs (assembly) takes place in the karyon of infected cells.
Essential to the present invention are therefore in particular recombinant papilloma virus-like particles which are formed after expression of the viral structural proteins L1 and/or L2, in which one or several sections of the L1 and/or L2 proteins are deleted, whereby the ability to form virus-like particles is increased in comparison to the native formation and/or in vitro production.
According to the present invention, at least one of the deleted sections in the L1 and/or L2 protein of a papilloma virus is a deletion, advantageously in the C-terminal amino acid sequence, preferably approximately 1 to 34 amino acids in length, preferably from 1 to 26 amino acids in length, in particular 26 amino acids in length.
Advantageously, after insertion of the C-terminal deletion into the L1 and/or L2 protein, the production of VLPs is increased many times, preferably at least 10 times, and in particular approx. to 100 times.
In a preferred embodiment of the present invention, the deleted sections in the L1 and/or L2 protein, in particular of the bovine papilloma virus, concern 26 C-terminal amino acids. Particularly preferred is the C-terminal deletion, 26 amino acids in length, (Gly-Ala-Gly-Cys-Ser-Thr-Val-Arg-Lys- Arg-Arg-lle-Ser-Gln-Lys-Thr-Ser-Ser- AlaProAla-Lys-Lys-Lys-Ly-Lys) corresponding to the S nucleotide positions 7016 to 7093 GGGGCACGAT GTTCAACTGT GAGAAAACGA AGAATTAGCC AAAAAACTTC CAGTAAGCCT GCAAAAAAAA AAAAAAA is inserted into the L1 ORF of the bovine papilloma virus type 1 (BPV Advantageously, after inserting the C-terminal deletion into the L1 and/or L2 protein, the production of VLPs is increased at least ten times.
According to a further embodiment of the present invention, the deletion, of which there is at o1 least one, in the L1 and/or L2 protein concerns a homologous amino acid sequence of the human papilloma virus 16 or of other papilloma viruses.
According to a further preferred embodiment, the deleted sections in the L1 and/or L2 protein concern 34 C-terminal amino acids of the human papilloma virus type 16 (HPV 16); preferably the amino acid sequence (Ala-Gly-Leu-Lys-Ala-Lys-Pro-Lys-Phe-Thr-Leu-Gly-Lys-Arg-Lys-Ala-Thr-Pro- Thr-Thr-Ser-Ser-Thr-Ser-Thr-Thr-Ala-Lys-Arg-Lys-Lys-Arg-Lys-Leu) corresponding to the nucleotide positions 7052 to 7153 GCAGGATTGA AGGCCAAACC AAAATTTACA TTAGGAAAAC GAAAAGCTAC ACCCACCACC TCATCTACCT CTACAACTGC TAAACGCAAA AAACGTAAGC TG, which is inserted into the L1 ORF of the HPV 16.
It is particularly preferred if the deletion of the L1 and/or L2 protein comprises the nuclear localisation signal (NLS). Particle production from the L1 proteins or the L1 proteins and L2 proteins takes place in particular in the cytoplasm. Preferably, the particles are secreted into the supematant liquid; particularly preferred is a secretion of approx. 5 to 10% of the particles.
The expression of L1 proteins or L1 proteins and L2 proteins in E. coli takes place according to a further preferred embodiment. In this at the C-terminal deletion in the L1 protein, in particular in addition 6 histidines are inserted. Advantageously the production of VLPs takes place after expression of 1 proteins or L1 and L2 proteins in E. coli.
According to the present invention, the further deleted sections in the L1 protein of the bovine papilloma virus type 1 preferably concern the amino acid sequences 311-351, 331-371, 391-431.
Advantageously the L1 proteins of the human papilloma virus 16 concern the amino acid sequence 306-315.
In a preferred embodiment of the present invention, the further deleted section of L1 and/or L2 proteins is replaced by other proteins or protein fragments, whereby proteins are obtained which in this document are called fusion proteins. Advantageously, the content of L1 or L2 protein is approx.
to 99%, preferably approx. 60 to 90%, particularly preferred approx. However, according to the present invention, even if this is not explicitly stated, more than one further section of the L1 and/or L2 protein should be deleted and preferably be replaced by other proteins or protein fragments.
It is particularly preferred if the deleted section of L1 or L2 protein is replaced by other proteins of papilloma viruses and/or proteins of other origin, whereby hybrid virus-like particles (HVLPs) -an be produced.
It has been shown particularly advantageous according to the present invention, that the formation of the VLPs takes place from an L1 protein an L1 fusion protein, an L1 protein and an L2 protein, an L1 fusion protein and an L2 protein, an L1 protein and an L2 fusion protein or an L1 fusion 1o protein and an L2 fusion protein.
According to a further embodiment of the present invention, at least one of the deleted sections in the L1 andlor L 2 protein of a papilloma virus concems N-terminal amino acid sequences.
According to the present invention, in a further embodiment at least one of the deleted sections in the L1 protein and/or L 2 protein of a papilloma virus concerns amino acid sequences in the middle Is section of the protein.
Also essential for the invention are proteins, in particular for the formation of hybrid papilloma virus-like particles, whereby one or several sections of the L1 and/or L2 protein are deleted. In particular, at least one of the deleted sequences in the L1 and/or L2 protein concerns the deletion of a C-terminal amino acid sequence.
The fusion proteins, in particular for the formation of hybrid papilloma virus-like particles according to a further embodiment of the present invention, advantageously consist of a deleted L1 and/or L2 protein of different papilloma viruses, especially preferred are HPV 6, 11, 16, 18, 31, 33, and 45, and other proteins or protein fragments of papilloma viruses or of other origin. Preferably, these other proteins or protein fragments concern the respective early papilloma virus proteins or fragments thereof, such as for example the early proteins El, E2, E4, E5, E6 and/or E7.
According to the process covered in the invention, the expression of the proteins and/or fusion proteins and the production of papilloma virus-like particles is carried out in viral, eukaryotic or prokaryotic vectors, especially advantageous in vaccinia recombinants, in baculoviruses, in yeasts or in bacteria, in particular in E coil.
Preferably particle production occurs in cytoplasm. In a particularly preferred manner, the particles are secreted into the supernatant liquid; it is particularly preferred if approx. 5 to 10% of the particles are secreted into the supernatant liquid.
In particular, according to the present invention, by inserting a C-terminal deletion, 26 amino acids in length, into the nucleotide positions 7016 to 7093 in the L1 ORF of the bovine papilloma virus 3s type 1 (BPV the production of VLPs is increased more than tenfold. Thus with the same quantity of L1 protein, as can be demonstrated for example in a Western blot, an increase in the particle number
I
can be demonstrated in the electron microscope. Since deletion preferably comprises the nuclear localisation signal (NLS), the particle production takes place in the cytoplasm, a significant part of the particles is secreted into the supernatant liquid. This is particularly advantageous because it significantly facilitates purification.
Proteins, preferably with the mentioned deletion with additional 6 histidines (His L1 proteins), according to the present invention are expressed in E. col. The proteins, in particular His L1 proteins, are preferably purified by way of Ni affinity chromatography, whereby according to an advantageous embodiment, at this point in time the proteins are present in a denaturation buffer, for example 6M guanidine hydrochloride. Renaturation takes place for example in 150mM NaCI, 1mM CaCl 2 0.01% Triton-X 100, 10mM Hepes (N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid), pH7.4.
According to a preferred embodiment of the present invention, production (assembly) of the VLPs takes place after dialysis of the proteins, preferably after dialysis against 150mM NaCI, Ca 2 10% DMSO (dimethylsulfoxide), 0.1% Triton-X 100, 10mM tris [tris-(hydroxymethyl) aminomethane] acetic acid with a pH value of The deletion of sequences in the L1 protein of all papilloma viruses which prevent the premature assembly of the VLPs leads to a higher yield during VLP production.
As far as in these cases the L1 NLS is concerned, the assembly takes place in the cytoplasm.
Consequently, according to the invention, purification of the VLPs is possible from the cytoplasm, instead of, as up to now, from the karyon. According to the invention, shorter deletions are also possible. According to the present invention, deletions of up to one amino acid and/or substitutions of up to one amino acid are carried out. In this it is advantageous that with short deletions or substitutions of up to one or only a few amino acids, the antigenic properties of the proteins and the VLPs formed thereof, are changed as little as possible when compared to the native antigenic properties of the proteins or VLPs.
The introduction of a C-terminal deletion or substitution in L1 and/or L2 fusion proteins, as carried out previously, also leads to an increase in the production of hybrid VLPs. In this, those VLPs should also be included which only contain L1 fusion proteins, as well as hybrid VLPs which contain an L1 or L2 fusion protein and an L2 or L1 protein.
For this, VLPs are produced which comprise fusion proteins of late and early HPV proteins (or fragments thereof) (HVLPs) and which can be used for prophylactic or therapeutic vaccination. Such a vaccine offers the following advantages when compared with conventional preparations: a) In the case of prophylactic vaccination, HVLPs, through induction of L1/L2-specific antibodies not only prevent entry of the virus into the cell but they also eliminate already infected cells (through induction of cytotoxic T-cells) if an infection has taken place earlier or if the humoral immune response was inadequate.
I
b) In the case of therapeutic vaccination, HVLPs eliminate persistently infected cells (eg. in patients with CIN or cervical carcinoma), and above all they prevent re-infection in female patients with CIN lesions.
c) Purification of ,he HVLPs is simple, in a similar way to purification of the VLPs without s early HPV proteins.
VLPs of the bovine papilloma virus (BPV) type 1 and the human papilloma viruses 11 and 16 after expression of L1 plus L2, or of L1 on its own, an be produced in vaccinia or baculovirus.
Experiments show that parts of the L1 protein can be deleted (amino acid sequences 311-351, 331- 371, 391-431 of BPV 1; 306-315 of HPV 16), without the ability to form VLPs being lost. Such sections o1 exist in the L1 proteins of all papilloma viruses so that the deleted section of L1 can be replaced by other proteins (of papilloma viruses or of other origin) and that in this way, hybrid virus-like particles can be produced. In the same way, parts of the papilloma virus protein L2 are deleted and replaced by other (early HPV or other) proteins, so that HVLPs can also be formed from the complete L1 protein plus an L2 fusion protein.
Fusion proteins comprising deleted L1 or L2 protein from different HPV types (mainly HPV 6, 11, 16, 18, 33, 35, 45) and the respective early proteins El, E2, E4, E5, E6, E7 (or parts thereof) are produced by expression in vaccinia recombinants which can be constructed in a very short time.
The formation of VLPs, consisting either of an L1 fusion protein or of the complete L1 protein plus an L2 fusion protein, is monitored by electron microscopy, and the presence of the early HPV protein is tested by Western blot analysis by means of specific antisera. For large-scale production of HPLVs the expression of the proteins in viral eukaryotic or prokaryotic systems, preferably in baculovirus, in yeast, or in E. coli, is carried out.
According to the present invention, the application of the fusion proteins or the hybrid virus-like particles for the production of a prophylactic and therapeutic vaccine preferably takes place after adding further components.
Respective experiments for producing fusion proteins can be carried out with proteins of other origin.
Claims (29)
1. Recombinantly produced papilloma virus-like particles which are formed after expression of viral structural proteins L1 and/or L2, wherein one or more sections of the L1 and/or L2 proteins are deleted without loss of the ability to form virus-like particles.
2. The virus-like particles according to claim 1, wherein the deleted section in the L1 protein is one or more of amino acid sequences 311-351, 331-371, 391-431 of the bovine papilloma virus type 1.
3. The virus-like particles according to claim 1, wherein the deleted section in the L1 protein is amino acid sequence 306-315 of the human papilloma virus 16.
4. Recombinantly produced papilloma virus-like particles which are formed after expression of viral structural proteins L1 and/or L2, wherein one or more sections of the L1 and/or L2 proteins are deleted and the ability to form virus-like particles is increased in comparison to native formation and/or in vitro production. The virus-like particles according to claim 4, wherein at least one of the deleted sections in the L1 and/or L2 protein of a papilloma virus is a C-terminal amino acid sequence.
6. The virus-like particles according to claim 5, wherein the deleted section in the C- terminal section in the L1 and/or L2 protein relates to an amino acid sequence approximately 1 to 34 amino acids in length of a papilloma virus.
7. The virus-like particles according to any one of claims 4 to 6, wherein the production of VLPs is increased many times over, preferably at least 10 times.
8. The virus-like particles according to any one of claims 4 to 7, wherein the deleted section in the LI and/or L2 protein is 26 C-terminal amino acids of the bovine papilloma virus.
9. The virus-like particles according to claim 8, wherein the C-terminal deletion, 26 amino acids in length, (Gly-Ala-Gly-Cys-Ser-Thr-Val-Arg-Lys-Arg-Arg-Ile-Ser-Gln- 11 Lys-Thr-Ser-Ser-Lys-Pro-Ala-Lys-Lys-Lys-Lys-Lys) corresponding to the nucleotide positions 7016 to 7093 GGGGCAGGAT GTTCAACTGT GAGAAAACGAAGAATTAGCC AAAAAACTTC CAGTAAGCCT GCAAAAAAAA AAAAAAA of the L1 ORF of the bovine papilloma virus type 1. The virus-like particles according to any one of claims 4 to 7, wherein the deleted section in the L1 and/or 12 protein is 34 C-terminal amino acids of the human papilloma virus type 16 (HPV 16).
11. The virus-like particles according to claim 10, wherein the C-terminal deletion is 34 amino acids in length, (Ala-Gly-Leu-Lys-Ala-Lys-Pro-Lys-Phe-Thr-Leu-Gly-Lys- Arg-Lys-Ala-Thr-Pro-Thr-Thr-Ser-Ser-Thr-Ser-Thr-Thr-Ala-Lys-Arg-Lys-Lys-Arg- Lys-Leu) corresponding to the nucleotide positions 7052 to 7153 GCAGGATTGA AGGCCAAACC AAAATTTACA TTAGGAAAAC GAAAAGCTAC ACCCACCACC TCATCTACCT CTACAACTGC TAAACGCAAA AAACGTAAGC TG in L1 ORF of the human papilloma virus type 16 (HPV 16).
12. The virus-like particles according to any one of claims 4 to 7, wherein the deletion in the C-terminal section in the L1 and/or L2 protein is an amino acid sequence homologous to the human papilloma virus 16 or to other papilloma viruses.
13. The virus-like particles according to any one of claims 4 to 12, wherein the deletion of the L1 and/or L2 protein comprises the nuclear localization signal (NLS).
14. The virus-like particles according to any one of claims 4 to 13, wherein particle production takes place in the cytoplasm. The virus-like particles according to any one of claims 4 to 14, wherein particles are secreted into the supernatant.
16. The virus-like particles according to claim 15, wherein approximately 5 to of the particles are secreted into the supernatant. -12-
17. The virus-like particles according to any one of claims 4 to 16, wherein the expression of L1 proteins or L1 and L2 proteins takes place in E. coli.
18. The virus-like particles according to claim 17, wherein at the C-terminal deletion in L1 protein, 6 histidine amino acid residues are inserted.
19. The virus-like particles according to claim 17 or claim 18, wherein the production of VLPs takes place after expression of L1 proteins or L1 and L2 proteins in E. coli. The virus-like particles according to any one of claims 4 to 19, wherein the further deleted section in the L1 protein is one or more of the amino acid sequences 311- 351, 331-371, 391-431 of the bovine papilloma virus type 1.
21. The virus-like particles according to claim 19, wherein the further deleted section in the L1 protein is the amino acid sequence 306-315 of the human papilloma virus 16.
22. The virus-like particles according to any one of claims 4 to 21, wherein at least one of the deleted sections in the L1 and/or L2 protein of a papilloma virus is an N- terminal amino acid sequence.
23. The virus-like particles according to any one of claims 4-22, wherein at least one of the deleted sections in the L1 and/or L2 protein is an internal amino acid sequence in the protein.
24. A process for the production of papilloma virus-like particles according to any one of claims 4 to 23, wherein the expression of L1 and/or L2 proteins is carried out in viral, eukaryotic or prokaryotic vectors. The process according to claim 24, wherein L1 and /or L2 proteins are produced by expression in vaccinia recombinants.
26. The process according to claim 24, wherein the expression of the L1 and/or L2 proteins is carried out in baculoviruses or in yeasts. -13-
27. The process according to claim 24, wherein the expression of the L1 and/or L2 proteins is carried out in E. coli.
28. The process according to claim 27, wherein purification, in particular of the L1 proteins, takes place by Ni-affinity chromatography and renaturation, preferably in 150 mM NaCI, 1 mM CaCl 2 0.01% Triton-X 100, 10 mM Hepes pH 7.4.
29. The process according to claim 28, wherein the proteins, at the time of purification, are present in a denaturation buffer. The process according to claim 29, wherein the denaturation buffer is 6 M guanidine hydrochloride.
31. The process according to any one of claims 24 to 30, wherein assembly of the VLPs takes place after dialysis.
32. The process according to claim 31, wherein dialysis takes place against 150 mM NaC1, 25 mM Ca 2 10% DMSO, 0.1% Triton-X 100, and 10 mM Tris acetic acid at pH
33. The process according to any one of claims 24 to 32, wherein particle production takes place in the cytoplasm.
34. The process according to any one of claims 24 to 33, wherein particles are secreted into the supernatant. The process according to claim 34, wherein approximately 5 to 10% of the particles are secreted into the supernatant.
36. Use of the virus-like particles according to any one of claims 1 to 3, or, 4 to 23 for the production of a vaccine for prophylactic and/or therapeutic vaccination, preferably after adding further components DATED this 1 1 th day of May 2004 BALDWIN SHELSTON WATERS Attorneys for: LOYOLA UNIVERSITY OF CHICAGO
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003235191A AU2003235191B2 (en) | 1994-10-07 | 2003-08-19 | Papilloma virus-like particles, fusion proteins as well as processes for their production |
| AU2006252125A AU2006252125B2 (en) | 1994-10-07 | 2006-12-19 | Papiloma virus-like particles, fusion proteins as well as processes for their production |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4435907 | 1994-10-07 | ||
| DE9526752 | 1995-07-21 | ||
| AU10106/00A AU760615B2 (en) | 1994-10-07 | 2000-01-05 | Papilloma Virus-like Particles, Fusion Proteins as Well as Processes for Their Production |
| AU2003235191A AU2003235191B2 (en) | 1994-10-07 | 2003-08-19 | Papilloma virus-like particles, fusion proteins as well as processes for their production |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU10106/00A Division AU760615B2 (en) | 1994-10-07 | 2000-01-05 | Papilloma Virus-like Particles, Fusion Proteins as Well as Processes for Their Production |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006252125A Division AU2006252125B2 (en) | 1994-10-07 | 2006-12-19 | Papiloma virus-like particles, fusion proteins as well as processes for their production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003235191A1 AU2003235191A1 (en) | 2003-09-18 |
| AU2003235191B2 true AU2003235191B2 (en) | 2006-09-21 |
Family
ID=39357326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003235191A Expired AU2003235191B2 (en) | 1994-10-07 | 2003-08-19 | Papilloma virus-like particles, fusion proteins as well as processes for their production |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2003235191B2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993002184A1 (en) * | 1991-07-19 | 1993-02-04 | The University Of Queensland | Papilloma virus vaccine |
| WO1994020137A1 (en) * | 1993-03-09 | 1994-09-15 | University Of Rochester | Production of human papillomavirus capsid protein and virus-like particles |
-
2003
- 2003-08-19 AU AU2003235191A patent/AU2003235191B2/en not_active Expired
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993002184A1 (en) * | 1991-07-19 | 1993-02-04 | The University Of Queensland | Papilloma virus vaccine |
| WO1994020137A1 (en) * | 1993-03-09 | 1994-09-15 | University Of Rochester | Production of human papillomavirus capsid protein and virus-like particles |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU760615B2 (en) | Papilloma Virus-like Particles, Fusion Proteins as Well as Processes for Their Production | |
| Jochmus et al. | Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine | |
| DE69836753T2 (en) | PAPILLOMA VIRUS CAPSOMERE VACCINE FORMULATIONS AND THEIR USES | |
| JP2007211026A (en) | Fake virus of papillomavirus and method for preparing the same | |
| EP1305039B1 (en) | Stable (fixed) forms of viral l1 capsid proteins, fusion proteins and uses thereof | |
| CA2691091C (en) | Fusion protein, macromolecule assembled from the fusion protein, and its use in the prevention or treatment of human papillomavirus related diseases | |
| EP1222200B1 (en) | Fusion protein between HPV-L1 and a peptide, capable of forming a VLP and that functions as a vehicle for introduction of a peptide in a cell and medical uses thereof | |
| US7182947B2 (en) | Papillomavirus truncated L1 protein and fusion protein constructs | |
| EP1105157A1 (en) | Protein delivery system using human papillomavirus virus-like particles | |
| AU2003235191B2 (en) | Papilloma virus-like particles, fusion proteins as well as processes for their production | |
| AU2006252125B2 (en) | Papiloma virus-like particles, fusion proteins as well as processes for their production | |
| DE19526752C2 (en) | Highly efficient formation of particles similar to papillomavirus | |
| US7494658B2 (en) | Papilloma virus truncated L1 protein and fusion protein constructs | |
| Deng et al. | The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro | |
| DE29521486U1 (en) | Papilloma virus-like particles | |
| HK1094340A (en) | Papilloma virus capsomere vaccine formulations and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| NC | Extension of term for standard patent requested (sect. 70) |
Free format text: PRODUCT NAME: CERVARIX HUMAN PAPILLOMAVIRUS VACCINE TYPES 16 AND 18 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PAPILLOMA VIRUS-LIKE PARTICLES, FUSION PROTEINS AS WELL AS PROCESSES FOR THEIR PRODUCTION |
|
| NDA | Extension of term for standard patent accepted (sect.70) |
Free format text: PRODUCT NAME: RECOMBINANT AS04 ADJUVANTED CERVARIX; 1ST REGULATORY APPROVAL DATE PROVIDED BY THE PATENTEE: 20070518 |
|
| PC | Assignment registered |
Free format text: FORMER OWNER WAS: LOYOLA UNIVERSITY OF CHICAGO THE EARLIEST FIRST REGULATORY APPROVAL DATE PROVIDED BY THE PATENTEE 18 MAY 2007 FOR THE GOODS CERVARIX HUMAN PAPILLOMAVIRUS TYPES 16 AND 18 EXTENSION OF TERM OF PATENT PURSUANT TO SECTION 77 EXPIRES ON 09 OCT |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired | ||
| NA | Applications received for extensions of time, section 223 |
Free format text: AN APPLICATION TO EXTEND THE TIME FROM 09 OCT 2015 TO 09 JUN 2016 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED . |
|
| NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 09 JUN 2016 Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 09 JUN 2016 . |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |